Oncotarget, The Driver of Medical Research

Oncotarget is an open-get to journal that is distributed by Impact Journal. It was begun in 2010 and is discharged online week by week. It generally distributes papers on oncology. Its central goal is to guarantee that all maladies are annihilated. The diary is listed in the Science Citation Index Expanded, Scopus, Index Medicus, and PubMed. Oncotarget is positioned profoundly among therapeutic diaries, particularly those that are open-get to. The diary has found the middle value of an effective component of 5.0 for as far back as five years. Its prosperity can be credited to the polished skill and mastery of the editors and the individuals from the article board. Visit his profile on Google Scholar.

The primary boss editors of Impact diary were Mikhail Blagosklonny and Andrei V. Gudcov. They are presently working at Rosewall Park Cancer Institute. The therapeutic diary is essentially critical on the grounds that it offers ingenious logical investigation. It likewise gives assistance to individuals who are either influenced or contaminated to have a superior comprehension to battle and handle the malady. In 2015, oncotarget was positioned number one among the numerous oncology diaries in the States.

The essential point of oncotarget is to end up noticeably one of the best restorative specialists in oncology. The therapeutic diary, Oncotarget distributed an article in 2015 that turned out to be useful. They called the report the effect of HuR obstacle by the little atom MS-444 on disease cells. The condition, tumor is one of the destructive infections introduce as of now more especially its branch security disease is positioned third as the best growth that causes demise. Since Oncortaget was set up, it has gone about as a stage where individuals share vital thoughts to produce conceivable arrangements.

An essential perspective about the medicinal diary is that it assumes an extremely noteworthy part in guiding the general population to comprehend oncology. The medicinal research diary people groups to get more data on the counteractive action and treatment of security tumor. Download output styles at Endnote.com

The editors are perceived experts in therapeutic research. Gudkov is a senior VP of medicinal research and an educator at the Institute. Blagosklonny is an oncology teacher. Its article board contains regarded researchers and scientists who have won various honors including the Lasker Prize and the Breakthrough Prize.

 

Eric Lefkofsky: Working Towards a Healthy Future

Eric Lefkofsky is a famous and renowned entrepreneur who recently founded Tempus. Tempus is a startup for cancer-fighting. Tempus specifically designed for medical practitioners and experts from the Chicago University to help others by searching better cure and treating breast cancer with advanced technology and methods.

Tempus, a Chicago-based company, recently announced a partnership with the Medicine department of Chicago University this Thursday to provide molecular analysis and sequencing to breast cancer specialists. This partnership is formed to make personalized plans for different patients according to their available funding, their priorities and what they want to do.

Experts at Tempus are working hard to properly analyze data before a huge number of the individual across the globe who are suffering from such life-threatening diseases so that they can learn the progress and to help researchers and doctors to uncover the patterns which can predict how the sick individual is going to respond to such treatment.

The goal for Tempus is that to provide a central database that everyone can use to save the time which would otherwise get wasted when a scientist is repeating the same experiment again and again from a different part of the world. Like if a scientist is doing experiments in America then he will update his finding on Tempus so that another scientist who is working on same cure can know that such process has already done and that was the finding so that he can skip repeating same procedure and proceed to next step. Click here to know more.

  1. OlufunmilayoOlopade once said to the media that although cancer of the breast is the diseases that millions of patients across the globe are suffering from it, there’s comparatively very little data available about those patients who’ve battled or still battling with that disease. And this was the reason of founding Tempus so that there would a centralized database would be available online so that anyone who wants can get access to it to collect the information that they need. That will not just help them to save time which otherwise gets wasted in the repetition of same procedures but also scientists to proceed toward the cure with more rapid pace.

www.forbes.com/profile/eric-lefkofsky

Dr. Clay B. Siegall – President and CEO of Seattle Genetics

On January 30, 2013, Mirna Therapeutics appointed Dr. Clay Siegall as an outside director to the company’s board of directors. Dr. Clay, Ph.D., is the co-founder, President and the current Chairman and Chief Executive Officer of the Board of Directors of Seattle Genetics. He was chosen as an outside director of Mirna Therapeutics due to his great experience in the production of pharmaceutical products geared in the fight against cancer. Mirna Therapeutics is a biotechnology company that specialized in the development of micoRNA therapeutics as well as its commercialization.
Dr. Clay Siegall graduated with a Ph.D. in Genetics from the George Washington University. He also holds a Bachelor of Science in Zoology degree from the University of Maryland. Prior to becoming the CEO of Seattle Genetics Dr. Siegall worked for the Bristol-Myers Squibb Pharmaceuticals Research Institute from 1991 to 1997. He had also worked at the National Institutes of Health and Cancer Institute from 1988 to 1991.
Seattle Genetics is a renowned biotechnology company that focuses on the development and commercialization of innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. Dr. Clay B. Siegall co-founded the Washington-based company in 1998. Under his leadership as the Chairman of the Board and CEO, Seattle Genetics has built a range of antibody-based therapies that aim to address the unmet needs of cancer patients. ADCETRIC is Seattle Genetics’ first commercial product which was approved in August 2011. ADCETRIS operates commercially in two indications in more than 50 countries including the United States, Canada, Japan and the EU. Throughout the years, the company has manufactured a wide pipeline of different product candidates. Seattle Genetics has also joined various strategic licenses for its ADC technology, including with companies such as Genentech, AbbVie, GSK and Pfizer under the leadership of Dr. Clay.
Seattle Genetics, whose initial public offering was in 2001, has engaged in capital-raising activities that have seen it secure more than $675 million under the leadership of Dr. Clay. He views MicroRNA-based therapeutics as an exciting area of cancer treatment and research. Mirna is indeed well positioned with an amazing pipeline of product candidates.

Sources:

http://www.pegsummit.com/uploadedFiles/PEGS/Agenda/15/PEGS-Interview-Siegall.pdf

http://www.mirnatherapeutics.com/pdfs/releases/2013%200130%20Mirna%20Siegall%20BOD.pdf

Everything you need to know about Seattle Genetics

Seattle Genetics is a leading biotechnology company, founded in 1998, that specializes in the development of antibody drug conjugates (ADCs) that work to kill cancer cells. These antibody-based therapies are created in conjunction with ADC and SEA technology. The company produces FDA approved products that are commercially available in 47 countries and counting. They address unmet medical needs through a robust product pipeline. As of July 2016, Seattle Genetics announces that their product, ADCETRIS, is the first in a new class of ADCs and, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available in 65 countries. As of now, the drug is being conducted in a broad clinical development program evaluating its potential to become the foundation of treatment for CD30-expressing lymphomas. In August 2016, Seattle Genetics announced positive data from phase 3 ALCANZA clinical trial of ADCETRIS for CD30-expressing cutaneous T-cell lymphoma. The company is publically traded, SGEN. As of June 30, 2016, the company has $659.5 million in cash and investments. The company also has 140 million common stock outstanding.

Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript

Clay Siegall is the co-founder, president and CEO of Seattle Genetics in 1998 located in Bothell, WA. He is presently a Chairman of the Board and has been there for 18 years. He has built the company into a leader and innovator of the biotechnology worlds through its multiple strategic licenses for its ADC technology that include Genentech (Roche), AbbVie, GlaxoSmithKline, and Pfizer. These have spawned more that $300 million to date. In addition, Seattle Genetics collaborates with both internal and external programs that amount to more than 20 ADCs in clinical development.

Siegall studied at the University of Maryland and obtained a Bachelor of Science (B.S.) in Zoology and then a Doctor of Philosophy (Ph.D.) in Genetics at The George Washington University. Before working for Seattle Genetics, Dr. Siegall worked for Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. Currently, he resides on the Board of Directors for three companies; Ultragenyx Pharmaceutical for 2 years, Mirna Therapies, Inc. for 3 years and Alder Biopharmaceuticals Inc. (Nasdaq: ALDR) for 10 years. Mirna and Alder BioPharmaceuticals are both private biotechnology companies.

He has received Entrepreneur of the Year for Pacific Northwest Ernst and Young in 2012 as well as Alumnus of the Year for Computer, Math and Natural Science at the University of Maryland in 2013.

https://www.linkedin.com/in/claysiegall

http://www.bloomberg.com/research/stocks/people/person.asp?personId=607509&privcapId=34145